Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Beats Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of +26.83% and +51.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?